Literature DB >> 538085

Hydergine: a review of 26 clinical studies.

R J McDonald.   

Abstract

This report reviews 26 clinical drug trials which investigated the effectiveness of Hydergine, a dihydrogenated ergot alkaloid, used frequently in geriatric psychopharmacology. The methodological characteristics and significant results for each study are presented in outline form. In total, 32 symptoms were assessed in six or more studies. Therapeutic benefits following Hydergine treatment occurred in the areas of cognitive dysfunctions, mood depression, and the composite scores as measured by subjective clinical behavioral rating scales. It is suggested that the improvement reported in cognitive functions and mood depression is a reflection of the global change observed by clinicians in patients' overall behavior duirng the interview. This conclusion that Hydergine does produce some global improvement indicates that further research with Hydergine is warranted, provided more objective instruments are employed such as those described in the report.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 538085     DOI: 10.1055/s-0028-1094637

Source DB:  PubMed          Journal:  Pharmakopsychiatr Neuropsychopharmakol        ISSN: 0031-7098


  7 in total

Review 1.  North of England evidence based guidelines development project: guideline for the primary care management of dementia.

Authors:  M Eccles; J Clarke; M Livingstone; N Freemantle; J Mason
Journal:  BMJ       Date:  1998-09-19

Review 2.  Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.

Authors:  C D Nicholson
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Rational drug treatment of dementia?

Authors:  J Byrne; T Arie
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-22

Review 4.  Critical review of clinical trials in senile dementia--II.

Authors:  J M Orgogozo; R Spiegel
Journal:  Postgrad Med J       Date:  1987-05       Impact factor: 2.401

Review 5.  Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline.

Authors:  A N Wadworth; P Chrisp
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

Review 6.  Advances in the pharmacotherapy of Alzheimer's disease.

Authors:  J C Soares; S Gershon
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

7.  Habituation of exploratory activity in mice: a screening test for memory enhancing drugs.

Authors:  A Platel; R D Porsolt
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.